|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| sessions | DNA damage responses | Translational research | Clinical radiotherapy | Radiation protection and ecology |
| 1 | DNA repair/Chromatin | Targeting DNA damage responses | Second cancers | Radiation induced carcinogenesis?? (here or another session) |
| 2 | DNA repair/Chromatin | Exosomes | Predicting responses: measuring radiosensitivity | Biomarkers (3 different types – sensitivity, cancer sensitivity, exposure) |
| 3 | Radiation signatures/sequencing studies | Nanotechnology for therapy | Revisiting fractionation | Epidemiology |
| 4 | High LET | Targeting high LET damage | Molecular imaging | Stem cells/regeneration |
| 5 | Space research+ neuroscience | Targeting brain tumours | Particle therapy I | Space research/neuroscience |
| 6 | Syndromes (interfaces with neuroscience | Use of microbeams | Particle therapy II | cardiology |
| 7 | Intercellular signalling (bystander+ abscopal) | Macrophage/intercell signalling/abscopal and tissue damage | Precision RT | Ecology |
| 8 | DDR in stem cells | Cancer stem cells | Modelling and theranostics | Stem cells/regeneration |
| 9.  | Oxidative damage (could be combined with chemistry) | Exploiting stem cells for therapy | Survivorship and patient perspectives | Radiation Protection |
| 10. | Hypoxia and DDR | identifying and targeting hypoxia | Hypoxia and the clinic | Modelling – internal radioisotopes |
| 11 | Epigenetics/non coding | Radiobiology meets immune biology | Radiogenomics | Public engagement |
| 12. | Chemistry | Normal tissue radiobiology | Immunotherapy | Guidelines/mitigation |
| 13. | Modelling basic responses | Checkpoints | Clinical trials show case | Psychology |
| 14 | Emerging technologies | Emerging technologies | Emerging technologies | Emerging technologies |